Undetectable baseline ctDNA significantly improves progression-free and overall survival in advanced NSCLC patients
Tumor DNA Levels Help Predict Outcomes in Lung Cancer Treatment
This meta-analysis of 2,107 patients evaluates the role of circulating tumor DNA (ctDNA) as a biomarker for outcomes in advanced NSCLC treat…
Testing for circulating tumor DNA may help doctors predict how well patients with advanced lung cancer respond to immunotherapy treatments.
Nab-paclitaxel provides moderate efficacy and manageable safety for advanced or recurrent small cell lung cancer
Nab-paclitaxel shows moderate results for advanced small cell lung cancer
This meta-analysis of 334 patients with advanced or recurrent small cell lung cancer found nab-paclitaxel achieved an overall response rate …
A new analysis shows nab-paclitaxel offers manageable safety and steady results for patients with advanced small cell lung cancer.
OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
Protein OTUD7B plays complex roles in cancer and heart health
This systematic review examines the molecular roles of OTUD7B across multiple malignancies and inflammatory models. The findings indicate th…
A protein called OTUD7B acts as a double-edged sword, helping some conditions while fueling the growth of others.
Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer
Immunotherapy combo extends survival in small cell lung cancer
This phase 3 RCT evaluated tislelizumab plus chemotherapy versus placebo plus chemotherapy in previously untreated extensive-stage small cel…
Adding tislelizumab to chemo helped people with extensive-stage small cell lung cancer live 2 months longer, a phase 3 trial shows.
Meta-analysis shows sublobar resection linked to worse survival outcomes compared with lobectomy for early-stage non-small cell lung cancer patients
Sublobar resection shows mixed survival results for early lung cancer
This umbrella review of meta-analyses indicates sublobar resection carries higher risks for overall and disease-free survival in Stage I non…
An umbrella review found mixed survival results for sublobar resection versus lobectomy in early-stage non-small cell lung cancer.
Machine learning models show moderate accuracy predicting neoadjuvant immunotherapy response in NSCLC
Machine learning models predict how well lung cancer patients respond to immunotherapy
This systematic review and meta-analysis of 44 models found that machine learning predicts neoadjuvant immunotherapy response in resectable …
A new analysis of 44 models shows computer programs can guess which lung cancer patients will benefit from immunotherapy, though the study h…
Meta-analysis links baseline and dynamic ctDNA to survival in advanced NSCLC
ctDNA in blood predicts survival in advanced lung cancer
This systematic review and meta-analysis of 43 studies found that detectable or elevated baseline plasma ctDNA was associated with worse ove…
A blood test for tumor DNA can predict survival in advanced lung cancer, helping guide treatment decisions.
Fianlimab plus cemiplimab showed objective response rates of 20% to 33% in advanced solid tumors during a Phase 1 study.
Early trial shows new cancer drug combo helps some patients with advanced disease
This Phase 1, first-in-human dose-expansion study evaluated fianlimab 1600 mg plus cemiplimab 350 mg in patients with advanced non-small cel…
A new drug combination helped some patients with advanced lung, kidney, head and neck, or skin cancer shrink their tumors in early testing.
Immune checkpoint inhibitors before lung cancer surgery show acceptable safety profile
Immunotherapy before lung cancer surgery is safe, study finds
This meta-analysis of patients with resectable non-small cell lung cancer found that neoadjuvant or perioperative immune checkpoint inhibito…
A new analysis of 2,691 patients shows that immunotherapy before lung cancer surgery is feasible, but comes with specific surgical challenge…
Cutaneous immune-related adverse events associated with improved progression-free survival in non-small cell lung cancer
Skin reactions in lung cancer patients may signal longer life with certain treatments
This meta-analysis evaluated patients with non-small cell lung cancer receiving anti-PD-1, PD-L1, or chemotherapy. The analysis found that c…
A large review found that specific skin reactions linked to cancer drugs are connected to longer survival times for some lung cancer patient…
Perspective review on radiation therapy and cardiac toxicity in lung cancer
Radiation planning may help protect heart and immune system in lung cancer patients
This perspective review article synthesizes evidence on thoracic radiation therapy for locally advanced non-small cell lung cancer, focusing…
A perspective review suggests radiation planning techniques could spare the heart and immune system for lung cancer patients.
Review of T cell engagers highlights potential for treating solid tumors and small cell lung cancer cases
Review of tarlatamab for solid tumors and small cell lung cancer
This review examines T cell engagers as a promising intervention for solid tumors, specifically small cell lung cancer. Current data suggest…
This review looks at tarlatamab, a T cell engager, for treating solid tumors and small cell lung cancer. It examines how these drugs work.
Research across Cancer
Related studies from across the Cancer family.
Guideline-based case report: neoadjuvant alectinib in ALK-rearranged stage IIIB lung cancer
One woman shows how alectinib shrinks lung cancer before surgery
This guideline-based case report describes a 57-year-old woman with ALK-rearranged stage IIIB lung cancer treated with neoadjuvant alectinib…
A single case shows alectinib shrinking lung cancer before surgery. This report offers hope for specific patients but needs more study.
Narrative review outlines multimodal decision-making for EGFR-mutant NSCLC with leptomeningeal metastasis
Doctors outline a pathway for treating lung cancer that spreads to the brain
This narrative review addresses patients with EGFR-mutant non-small cell lung cancer who develop resistance to tyrosine kinase inhibitors an…
This review outlines a clinical pathway to help physicians personalize treatment for lung cancer patients with brain spread.
Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion
One Drug Shrinks Lung Tumors When Others Stop Working
This is a case report and literature review of a 77-year-old female with EGFR-TKI-resistant advanced lung adenocarcinoma and malignant peric…
A 77-year-old woman with advanced lung cancer saw her tumors shrink and dangerous fluid around her heart disappear after trying a new drug c…
Post hoc reanalysis suggests stereotactic radiotherapy may improve local control in medically inoperable Stage I non-small cell lung cancer
New analysis gives hope for early lung cancer patients who cannot have surgery
This post hoc Bayesian reanalysis of the LUSTRE trial evaluated stereotactic radiotherapy versus conventional radiotherapy in medically inop…
A new statistical review suggests a focused radiation approach may better control early lung cancer for patients who cannot undergo surgery.
FDA Approves Enhertu (fam-trastuzumab deruxtecan-nxki) for Multiple HER2-Positive and HER2-Low Cancers
FDA approves Enhertu for several types of HER2 positive cancers.
FDA approved Enhertu for several indications including HER2-positive metastatic breast cancer, HER2-low and HER2-ultralow breast cancer, HER…
The FDA has approved Enhertu for multiple cancers, including breast, lung, stomach, and other solid tumors that have a specific protein call…
Network meta-analysis of anti-PD-1/PD-L1 regimens in advanced non-squamous NSCLC without EGFR or ALK alterations
New drugs beat old ones for advanced lung cancer survival
This systematic review and network meta-analysis evaluated overall survival and progression-free survival across 15 Phase III randomized cli…
New drug combinations show better survival chances for advanced lung cancer patients whether their tumors express PD-L1 or not
Review of IVIG and bronchoscopic interventions for pediatric EBV-SMT in immunodeficiency
A rare lung tumor in a boy with immune issues may need IVIG and bronchoscopic procedures
This case report review describes a 10-year-old boy with congenital immunodeficiency and an Epstein–Barr virus-associated smooth muscle tumo…
A single case report suggests IVIG and bronchoscopic procedures might help a rare lung tumor in children with immune problems, though recurr…
Deep hyperthermia with tislelizumab and chemotherapy in advanced squamous NSCLC
Deep Heat Plus Drug Boosts Lung Cancer Response Rates
This retrospective cohort study of 100 patients with advanced squamous NSCLC evaluated deep hyperthermia combined with tislelizumab and chem…
Adding deep heat to standard lung cancer treatment improved response rates significantly while keeping safety levels the same as standard ch…
Consolidation immunotherapy shows no survival benefit over induction alone in stage III non-small cell lung cancer
Adding immunotherapy after chemo may not help stage III lung cancer
This retrospective cohort study evaluated 196 patients with stage III non-small cell lung cancer across 4 hospitals.
Stage III lung cancer patients saw no clear survival gain when immunotherapy was added after chemo and radiation.
Camrelizumab Associated With Higher Progression Risk Versus Pembrolizumab in Nonsquamous NSCLC Cohort
Sintilimab May Be Safer Lung Cancer Treatment
This retrospective cohort study evaluated 409 patients with stage IIIB-IV non-small cell lung cancer receiving PD-1 inhibitors.
One lung cancer drug may cause fewer serious side effects than others while working just as well, a real-world study suggests.
Modified thin-slab volume rendering improves diagnostic performance for pneumonic-type lung cancer and inflammatory pneumonia
New Imaging Trick Tells Cancer and Pneumonia Apart
This retrospective cohort study evaluated modified thin-slab volume rendering (tsVR) with densitometry-derived thresholds against convention…
Doctors can now tell aggressive lung cancer apart from pneumonia more accurately using a simple tweak to CT scans that highlights subtle dif…
Double 8F ultrafine chest tubes reduced pain and complications compared to standard tubes in lung tumor patients
Smaller tubes mean less pain for lung tumor patients after surgery
This retrospective multicenter cohort study evaluated 1,076 lung tumor patients who underwent U-VATS.
Lung surgery patients feel significantly less pain and face lower bleeding risks when doctors use ultrafine drainage tubes instead of regula…
Questions about Extensive-Stage Small-Cell Lung Cancer
How does adding a PD-1 inhibitor to platinum-etoposide improve survival in extensive-stage small-cell lung cancer?
Adding a PD-1 inhibitor to platinum-etoposide improves overall survival by about 26% (HR 0.74) and progression-free survival by about 32% (HR 0.68) in ES-SCLC, based on meta-analyses of phase III trials.
Full answer →Does toripalimab plus anlotinib maintenance show promise for extensive-stage small-cell lung cancer?
Yes, a phase II trial found toripalimab plus anlotinib maintenance after first-line chemo led to median progression-free survival of 8.18 months and overall survival of 23.05 months in ES-SCLC.
Full answer →All Extensive-Stage Small-Cell Lung Cancer Articles
- Nab-paclitaxel provides moderate efficacy and manageable safety for advanced or recurrent small cell lung cancer
- Undetectable baseline ctDNA significantly improves progression-free and overall survival in advanced NSCLC patients
- OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
- Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer
- Meta-analysis shows sublobar resection linked to worse survival outcomes compared with lobectomy for early-stage non-small cell lung cancer patients
- Machine learning models show moderate accuracy predicting neoadjuvant immunotherapy response in NSCLC
- Meta-analysis links baseline and dynamic ctDNA to survival in advanced NSCLC
- Fianlimab plus cemiplimab showed objective response rates of 20% to 33% in advanced solid tumors during a Phase 1 study.
- Immune checkpoint inhibitors before lung cancer surgery show acceptable safety profile
- Cutaneous immune-related adverse events associated with improved progression-free survival in non-small cell lung cancer
- Perspective review on radiation therapy and cardiac toxicity in lung cancer
- Review of T cell engagers highlights potential for treating solid tumors and small cell lung cancer cases
- Observational study links ADAM9 expression to survival in lung adenocarcinoma patients
- Review of Non-small cell lung cancer without reported intervention or outcomes
- Systematic review and meta-analysis on neoadjuvant chemoimmunotherapy for resectable NSCLC
- Meta-analysis links emotional distress to worse outcomes in advanced lung cancer
- Systematic review and meta-analysis links higher prognostic nutritional index to better survival in non-small cell lung cancer
- Systematic review of intrathecal therapy for leptomeningeal metastasis in non-small cell lung cancer
- Case report suggests second primary glioblastoma in ALK-positive lung adenocarcinoma patient treated with ensartinib and lorlatinib
- Morning immune checkpoint inhibitor infusions associated with improved survival in metastatic non-small-cell lung cancer
- Meta-analysis of PET/CT metabolic parameters for predicting NSCLC response after neoadjuvant therapy
- FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
- Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion
- Case report on sequential therapy for MET exon 14 skipping NSCLC with high PD-L1
- Meta-analysis shows dual ICI therapy improves survival in advanced metastatic non-small cell lung cancer
- Post hoc reanalysis suggests stereotactic radiotherapy may improve local control in medically inoperable Stage I non-small cell lung cancer
- Meta-analysis of neoadjuvant anti-PD-1/PD-L1 plus chemotherapy in resectable NSCLC reports resection and response rates
- Narrative review explores Vaccinia virus therapy for non-small cell lung cancer with noted delivery challenges
- FDA Approves Lazcluze (lazertinib) with Amivantamab for EGFR-Mutant NSCLC
- Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
- Case report and review highlights ultrasound-guided microwave ablation for metastatic breast cancer in a single patient
- Narrative review covers hepatocellular carcinoma, colorectal cancer, glioblastoma, breast cancer, pancreatic cancer, and non-small cell lung cancer
- Real-world meta-analysis supports pembrolizumab for advanced NSCLC with high PD-L1
- RNK08954 shows unconfirmed responses in KRASG12D-mutant NSCLC and PDAC in Phase Ia trial
- Subcutaneous tislelizumab shows comparable trough concentrations to intravenous dosing in treatment-naive advanced non-small cell lung cancer patients
- Toripalimab plus anlotinib maintenance shows promise in ES-SCLC after first-line chemo
- Combination therapy shows promising progression-free survival in advanced non-small cell lung cancer patients with high PD-L1 expression
- Pembrolizumab improves overall survival versus chemotherapy in Chinese patients with advanced NSCLC and PD-L1 expression
- Meta-analysis shows platinum-etoposide plus PD-1/PD-L1 inhibitor improves survival in extensive-stage small-cell lung cancer
- Systematic review and meta-analysis shows immune checkpoint inhibitors improve survival in first-line ES-SCLC but not as single agents in second-line
- Network meta-analysis of anti-PD-1/PD-L1 regimens in advanced non-squamous NSCLC without EGFR or ALK alterations
- High tumour mutation burden improves overall survival in solid tumours treated with immune checkpoint inhibitors
- CT-based immune radiomic signature shows association with prognosis in non-small cell lung cancer
- Review examines thoracic radiotherapy combined with chemoimmunotherapy for extensive-stage small cell lung cancer patients
- Camrelizumab Associated With Higher Progression Risk Versus Pembrolizumab in Nonsquamous NSCLC Cohort
- Narrative review discusses tumor draining lymph nodes as a target for NSCLC therapy
- CIPHER model predicts immune checkpoint inhibitor pneumonitis risk in non-small cell lung cancer patients
- Magrolimab plus docetaxel shows limited efficacy in metastatic lung and urothelial cancers
- Review of 68Ga-Pentixafor PET/CT Utility in Lung Cancer Diagnosis and Management
- Narrative review examines abscopal effect potential in non-small cell lung cancer multimodality therapies
- Preoperative inflammatory markers linked to survival in resectable NSCLC
- Narrative review discusses osimertinib use in EGFR-mutated NSCLC patients with TKI resistance
- Narrative review summarizes bispecific antibodies and CAR T-cell therapy for advanced lung cancer
- Meta-analysis shows local consolidative therapy plus systemic therapy improves survival in driver-negative oligometastatic NSCLC
- Case Report Details Aumolertinib Rechallenge Following Osimertinib-Induced Interstitial Lung Disease in Lung Adenocarcinoma
- Narrative review examines driver mutations and immunotherapy response in non-small cell lung cancer
- Mini-review of phase III trial data on sublobar resection for small peripheral NSCLC
- Case report and literature review on T-SMARCA4-DUT diagnosis and treatment response in a single patient
- Review describes Virtual Spectral Decomposition framework for cancer imaging analysis
- Combined radiomics classifier predicts 3-year recurrence in surgically resected stage IA-IIIA non-small cell lung cancer
- Gene expression programs associated with survival and recurrence in early-stage lung adenocarcinoma patients
- HS-20093 shows response in lung cancers in Phase 1a/b trial
- Meta-analysis shows KRASG12C inhibitors improve outcomes versus chemotherapy in KRAS-mutant NSCLC
- Izalontamab brengitecan shows activity in pretreated NSCLC with non-classical actionable genomic alterations
- SABR shows 46% 5-year overall survival in unfit NSCLC patients in phase 2 trial
- NR2F2 expression in CAFs linked to poor prognosis and enhanced tumor progression in lung adenocarcinoma models
- In a phase 2 trial, [Ga]Ga-SSO120 PET/CT detected malignancies in 18 of 19 patients with small cell or large cell neuroendocrine lung cancer
- Setidegrasib shows antitumor activity in advanced NSCLC and pancreatic cancer with p.G12D variants
- First-line platinum-based chemotherapy associated with disease control and survival in recurrent NSCLC patients
- Phase Ib/II trial of nintedanib plus nivolumab in pretreated NSCLC adenocarcinoma shows 25% 6-month PFS rate
- First-line osimertinib shows high response rates in EGFR-mutated NSCLC with active brain metastases
- Concurrent TP53 and KRAS alterations show inconsistent survival impact across gastrointestinal cancers
- In Appalachian lung cancer patients, definitive chemoradiotherapy was associated with a 59% incidence of cardiovascular adverse events
- Predictive nomogram with spectral CT radiomics and deep learning features improves preoperative STAS prediction in surgically resected lung adenocarcinoma
- Meta-analysis shows radiomics-based machine learning models predict recurrence risk in non-small cell lung cancer patients
- AM.score predicts lung adenocarcinoma outcomes and immunotherapy response in a cohort of 1,720 patients
- AI-based PD-L1 scoring shows concordance with expert assessment in 333 NSCLC cases
- PD-1/PD-L1 inhibitors plus anti-angiogenic TKIs improve PFS but not OS in advanced NSCLC
- Eight-week mindfulness-based stress reduction reduced fatigue, anxiety, and depression in non-small cell lung cancer patients
- SBRT shows early QoL advantage over CHRT in inoperable stage I NSCLC, but long-term scores converge
- Firmonertinib plus anlotinib shows preliminary efficacy in advanced EGFR-mutant NSCLC
- Phase II studies evaluate tislelizumab plus sitravatinib or anlotinib maintenance in extensive-stage small-cell lung cancer
- Benmelstobart plus anlotinib improves progression-free survival versus pembrolizumab plus placebo in first-line PD-L1-positive advanced NSCLC
- BACE plus tislelizumab shows activity in advanced NSCLC patients ineligible for standard care
- Phase I study finds amrubicin-cisplatin with radiotherapy feasible in limited-stage SCLC
- Nivolumab with chemotherapy and bevacizumab shows improved 4-year survival in advanced nonsquamous NSCLC
- Rezivertinib improves CNS progression-free survival versus gefitinib in EGFR-mutated NSCLC with baseline CNS metastases
- Fulzerasib plus cetuximab shows 69% response in first-line KRAS-mutated NSCLC
- Phase 3 trial of pembrolizumab versus placebo after surgery for Stage IB-IIIA NSCLC posts results
- Radiomics-ML model predicts invasiveness in subcentimeter subsolid lung adenocarcinoma
- Global disparities persist in access to molecular diagnostics and novel therapies for advanced NSCLC
- Phase 2 trial finds no significant PFS benefit adding SABR to nivolumab in advanced NSCLC
- Perioperative tislelizumab plus chemotherapy improves survival in Chinese patients with resectable NSCLC
- CT-based radiomics shows variable accuracy for predicting occult lymph node metastasis in early-stage lung adenocarcinoma
- Amivantamab-lazertinib shows OS benefit over osimertinib in Asian EGFR-mutant NSCLC subset
- Phase III trial tests TTFields plus standard therapy for stage 4 NSCLC after platinum failure
- Phase 2 trial of DS-1062a in pretreated advanced NSCLC with genomic alterations posts no results
- Capmatinib shows efficacy in Chinese NSCLC patients with MET exon 14 skipping mutations
- VATS lobectomy improves overall survival vs open surgery in early-stage NSCLC
- Phase 2 trial of neoadjuvant/adjuvant pembrolizumab in stage IB-IIIA NSCLC completes enrollment of 35 patients
- Phase 2 Study: L-SABR Plus Standard Therapy in Metastatic NSCLC Patients